Skip to content
Home
About Us
Leadership
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Pipeline overview
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
Home
About Us
Leadership
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Pipeline overview
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
SVB Securities Global Biopharma Conference
February 16, 2023
February 16, 2023
8:00 am
Publications
Click here for Webcast
READ MORE
August 18, 2026
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Read More »
August 4, 2026
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
Read More »
July 31, 2026
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Read More »
See all News
